Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Appoints Scott Wasserman to Board; Dennis Berman Resigns

Neutral Impact 2 of 5 leadership Written later

Inhibikase Therapeutics appointed Scott Wasserman, MD, as a Class III director effective October 19, 2026, and Dennis Berman resigned from the board the same day. The change involves board and committee seats rather than operations, and the company said Berman's resignation was not due to any disagreement with management.

Key points

  • Scott Wasserman, MD, currently Chief Medical Officer of Kailera Therapeutics, joins the board effective October 19, 2026, and will serve on the Compensation Committee.
  • Wasserman receives an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of common stock.
  • Dennis Berman resigned from the board effective October 19, 2026, including his roles as Compensation Committee chair and Audit Committee member.
  • The company's board has determined Wasserman is independent under Nasdaq listing standards and SEC rules.

The filing

CompanyInhibikase Therapeutics, Inc. (IKT)
Form8-K, current report
Filed with the SECOct 20, 2026, 4:57 PM ET
Accession number0001193125-26-426811

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.